PE20140636A1 - Conjugado de naloxol-peg cristalino - Google Patents

Conjugado de naloxol-peg cristalino

Info

Publication number
PE20140636A1
PE20140636A1 PE2013000652A PE2013000652A PE20140636A1 PE 20140636 A1 PE20140636 A1 PE 20140636A1 PE 2013000652 A PE2013000652 A PE 2013000652A PE 2013000652 A PE2013000652 A PE 2013000652A PE 20140636 A1 PE20140636 A1 PE 20140636A1
Authority
PE
Peru
Prior art keywords
naloxol
mpeg7
salt
suspension
dissolved
Prior art date
Application number
PE2013000652A
Other languages
English (en)
Inventor
Bengt Leonard Aslund
Carl-Johan Aurell
Martin Hans Bohlin
Tesfai Sebhatu
Bo Ingvar Ymen
Eric Thomas Healy
David Richard Jensen
David Thomas Jonaitis
Stephan Parent
Original Assignee
Astrazeneca Ab
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45893441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Nektar Therapeutics filed Critical Astrazeneca Ab
Publication of PE20140636A1 publication Critical patent/PE20140636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/06—Oxalic acid
    • C07C55/07—Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

SE REFIERE A UNA SAL CRISTALINA DE OXALATO DE NALOXOL-POLIETILENGLICOL DE FORMULA (I) QUE PRESENTA VALORES d(�) DE LOS PICOS DE DIFRACCION DE RAYOS X EN POLVO DE 13.2; 7.9; 7.0; 6.6; 6.0; 5.7; 5.2; 5.1; 4.44; 4.39; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y A UN METODO PARA PRODUCIR DICHA SAL CRISTALINA, EL CUAL COMPRENDE: A) DISOLVER LA BASE LIBRE DE mPEG7-O-NALOXOL EN 2 VOLUMENES DE ACETONITRILO; B) ANADIR 3 EQUIVALENTES DE AGUA A LA SOLUCION DE mPEG7-O-NALOXOL DISUELTO; C) ANADIR ACIDO OXALICO EN ACETATO DE ETILO AL mPEG7-O-NALOXOL DISUELTO DURANTE 2 HORAS PARA PRODUCIR UNA SUSPENSION; Y D) FILTRAR LA SUSPENSION PARA OBTENER LA SAL DE TIPO OXALATO DEL CONJUGADO DE NALOXOL-POLIETILENGLICOL EN FORMA SOLIDA
PE2013000652A 2010-09-30 2011-09-29 Conjugado de naloxol-peg cristalino PE20140636A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38850110P 2010-09-30 2010-09-30

Publications (1)

Publication Number Publication Date
PE20140636A1 true PE20140636A1 (es) 2014-06-18

Family

ID=45893441

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000652A PE20140636A1 (es) 2010-09-30 2011-09-29 Conjugado de naloxol-peg cristalino

Country Status (39)

Country Link
US (2) US9012469B2 (es)
EP (2) EP2992903B8 (es)
JP (1) JP6034789B2 (es)
KR (1) KR101791724B1 (es)
CN (1) CN103237547B (es)
AR (1) AR083268A1 (es)
AU (1) AU2011307608B8 (es)
BR (1) BR112013007113B1 (es)
CA (1) CA2812649C (es)
CL (1) CL2013000866A1 (es)
CO (1) CO6700851A2 (es)
CR (1) CR20130146A (es)
CU (1) CU24317B1 (es)
DK (1) DK2621496T4 (es)
EA (1) EA023929B1 (es)
EC (1) ECSP13012531A (es)
ES (2) ES2819305T3 (es)
GT (1) GT201300084A (es)
HK (1) HK1187248A1 (es)
HR (1) HRP20151420T4 (es)
HU (1) HUE026726T2 (es)
IL (1) IL225308A0 (es)
ME (1) ME02313B (es)
MX (1) MX2013003587A (es)
MY (1) MY173890A (es)
NI (1) NI201300034A (es)
NZ (1) NZ609874A (es)
PE (1) PE20140636A1 (es)
PL (1) PL2621496T5 (es)
PT (1) PT2621496E (es)
RS (1) RS54488B8 (es)
SA (1) SA111320808B1 (es)
SG (1) SG188474A1 (es)
SI (1) SI2621496T2 (es)
SM (1) SMT201600004B (es)
TW (1) TWI518088B (es)
UA (1) UA112847C2 (es)
UY (1) UY33643A (es)
WO (1) WO2012044243A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6034789B2 (ja) 2010-09-30 2016-11-30 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 結晶性ナロキソール−ｐｅｇ接合体
JP6384964B2 (ja) * 2012-10-30 2018-09-05 ネクター セラピューティクス オピオイド作動薬としてのα−６−ＭＰＥＧ６−Ｏ−ヒドロキシコドンの固体塩およびその使用
NZ735736A (en) * 2015-03-10 2019-02-22 Rhodes Tech Acetate salt of buprenorphine and methods for preparing buprenorphine
CN107033154B (zh) 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN107033155B (zh) * 2016-02-04 2019-04-26 国药集团国瑞药业有限公司 一种吗啡酮类化合物的立体选择性还原方法
EP3228307A1 (en) 2016-04-05 2017-10-11 Sandoz Ag Solid dispersion comprising opioid antagonists
CN107303392A (zh) * 2016-04-19 2017-10-31 石家庄蒎格医药科技有限公司 一种聚乙二醇-纳洛酮组合物及应用
US11077103B2 (en) * 2016-11-23 2021-08-03 Aurobindo Pharma Ltd. Naloxegol oxalate and solid dispersion thereof
US11373198B2 (en) * 2016-12-02 2022-06-28 Honda Motor Co., Ltd. Evaluation device, evaluation method, and evaluation program
WO2019058387A1 (en) * 2017-09-19 2019-03-28 Msn Laboratories Private Limited, R&D Center IMPROVED PROCESS FOR THE PREPARATION OF (5Α, 6Α) -17-ALLYL-6- (2,5,8,11,14,17,20-HEPTAOXADOCOSAN-22-YLOXY) -4,5-EPOXYMORPHINANE-3,14-DIOL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
CN114137133B (zh) * 2021-12-03 2023-06-09 北京尚修堂医药科技有限公司 一种纳洛醇-peg衍生物有关物质的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507136A (en) 1949-02-19 1950-05-09 New York Quinine And Chemical Alkaloid purification
EP0668764A1 (en) * 1992-09-21 1995-08-30 QIN, Bo-yi Methods for identifying and using low/non-addictive opioid analgesics
JP4465109B2 (ja) 1997-12-17 2010-05-19 エンゾン ファーマシューティカルズ，インコーポレーテッド アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
EP0995757A3 (en) 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
MXPA02006216A (es) 1999-12-22 2004-02-26 Nektar Therapeutics Al Corp Derivados estericamente impedidos de polimeros solubles en agua.
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001257577A1 (en) 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
JP2004514701A (ja) 2000-11-30 2004-05-20 ネクター　セラピューティクス　エーエル，コーポレイション トリアジン誘導体の水溶性ポリマー複合体
DK1349855T3 (da) 2000-12-22 2006-12-27 Smithkline Beecham Plc 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl)thiazolidin-2,4-dionmesylatsalt
DK1362053T3 (da) 2001-02-20 2008-03-10 Enzon Inc Terminalt forgrenede polymere linkere og polymere konjugater indeholdende disse
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6756354B2 (en) 2001-09-05 2004-06-29 Deanna Jean Nelson Therapeutic compositions containing oligo (ethylene glycol)-terminated 1,2-dithiolanes and their conjugates
EP2939696B1 (en) 2001-10-18 2016-03-09 Nektar Therapeutics Polymer conjugates of opioid antagonists
US20030143185A1 (en) 2001-10-29 2003-07-31 Shearwater Corporation Polymer conjugates of protein kinase C inhibitors
CA2464346A1 (en) 2001-10-30 2003-05-08 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of retinoic acid
EP2243471A1 (en) 2002-04-05 2010-10-27 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
EP1694347B1 (en) 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
NZ594834A (en) * 2003-12-16 2013-03-28 Nektar Therapeutics Method of preparing PEGylated protein molecules
US8320574B2 (en) * 2006-04-20 2012-11-27 Hewlett-Packard Development Company, L.P. Methods and systems for reducing acoustic echoes in communication systems
EP2010539B1 (en) 2006-04-21 2017-06-14 Nektar Therapeutics Stereoselective reduction of a morphinone
EA201100544A1 (ru) * 2006-11-07 2012-01-30 Нектар Терапьютикс Применение комбинации опиоидного агониста и конъюгата полимер-опиоидный антагонист для изготовления лекарственного средства для лечения и предупреждения боли
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
EA201001643A1 (ru) 2008-05-07 2011-06-30 Нектар Терапеутикс Пероральное введение периферически действующих опиоидных антагонистов
EP2456469A1 (en) 2009-07-21 2012-05-30 Nektar Therapeutics Oligomer-opioid agonist conjugates
JP6034789B2 (ja) 2010-09-30 2016-11-30 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 結晶性ナロキソール−ｐｅｇ接合体

Also Published As

Publication number Publication date
GT201300084A (es) 2015-01-16
PT2621496E (pt) 2016-02-01
CU20130047A7 (es) 2013-08-29
AU2011307608B2 (en) 2015-04-09
KR101791724B1 (ko) 2017-10-30
EP2621496B1 (en) 2015-12-16
BR112013007113A2 (pt) 2017-07-25
RS54488B8 (sr) 2022-11-30
SI2621496T2 (sl) 2019-04-30
ES2819305T8 (es) 2022-05-26
PL2621496T5 (pl) 2019-05-31
AU2011307608B8 (en) 2015-08-27
SA111320808B1 (ar) 2014-12-15
CN103237547A (zh) 2013-08-07
NZ609874A (en) 2014-10-31
CO6700851A2 (es) 2013-06-28
WO2012044243A1 (en) 2012-04-05
SI2621496T1 (sl) 2016-02-29
RS54488B1 (en) 2016-06-30
HRP20151420T4 (hr) 2019-04-05
HK1187248A1 (zh) 2014-04-04
ES2562643T5 (es) 2019-05-24
NI201300034A (es) 2014-01-23
CA2812649A1 (en) 2012-04-05
ECSP13012531A (es) 2013-06-28
SG188474A1 (en) 2013-05-31
CR20130146A (es) 2013-05-15
EP2992903A1 (en) 2016-03-09
CA2812649C (en) 2016-03-01
US9012469B2 (en) 2015-04-21
SMT201600004B (it) 2016-02-25
KR20130135844A (ko) 2013-12-11
EP2992903B8 (en) 2022-06-08
HRP20151420T1 (hr) 2016-01-29
TWI518088B (zh) 2016-01-21
US20150038524A1 (en) 2015-02-05
EP2621496A1 (en) 2013-08-07
RS54488B2 (sr) 2019-03-29
ES2562643T3 (es) 2016-03-07
AR083268A1 (es) 2013-02-13
MX2013003587A (es) 2013-05-31
EA023929B1 (ru) 2016-07-29
CU24317B1 (es) 2018-02-08
AU2011307608A1 (en) 2013-05-02
EA201300423A1 (ru) 2013-09-30
US20150283257A1 (en) 2015-10-08
CN103237547B (zh) 2015-10-07
ME02313B (me) 2016-06-20
TW201307356A (zh) 2013-02-16
BR112013007113B1 (pt) 2020-09-24
UY33643A (es) 2012-04-30
EP2621496A4 (en) 2014-09-24
UA112847C2 (uk) 2016-11-10
CL2013000866A1 (es) 2013-08-30
US9149539B1 (en) 2015-10-06
MY173890A (en) 2020-02-26
HUE026726T2 (en) 2016-07-28
KR101791724B9 (ko) 2022-06-16
DK2621496T3 (en) 2016-01-18
EP2621496B2 (en) 2018-12-12
ES2562643T8 (es) 2022-07-12
JP6034789B2 (ja) 2016-11-30
PL2621496T3 (pl) 2016-05-31
IL225308A0 (en) 2013-06-27
ES2819305T3 (es) 2021-04-15
JP2013538849A (ja) 2013-10-17
AU2011307608A8 (en) 2015-08-27
EP2992903B1 (en) 2020-07-15
DK2621496T4 (en) 2019-03-18

Similar Documents

Publication Publication Date Title
PE20140636A1 (es) Conjugado de naloxol-peg cristalino
AR066130A1 (es) Formas cristalinas de saxagliptina y procesos para preparar las mismas
ES2656239T3 (es) Método de preparación de la forma cristalina I del racemato de 4-hidroxido-2-oxo-1-pirrolidina-acetamida
HRP20171175T1 (hr) Novi triciklički spojevi
MX345764B (es) Métodos para preparar glicoesfingolípidos y usos de los mismos.
AR057034A1 (es) Metodos para purificar tigeciclina
RU2014129742A (ru) Производные бензолсульфонамида в качестве модуляторов rorc
HRP20161103T1 (hr) Kemijski spojevi
CU20150014A7 (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
SI2935307T1 (en) Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures
AR073263A1 (es) Derivados de piridina y su uso en diagnostico de imagenes mediante pet
AR078151A1 (es) Conjugados de acidos grasos y niacina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades metabolicas.
PE20141160A1 (es) Metodos para preparar analogos nucleotidicos antivirales
EA201270216A1 (ru) Фармацевтический состав
AR084408A1 (es) Compuestos de purina y 7-deazapurina substituidos
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
UY32490A (es) Inhibidores de beta-secretasa
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CL2011003072A1 (es) Compuestos derivados de 4´-(isoxazol-5-il)-bifenil-4-il-cicloalquil(c3-8), antagonistas del receptor de acido lisofosfatidico; composicion farmaceutica que los comprende; y sus usos en el tratamiento del cancer, problemas pulmonares, entre otras.
NZ703162A (en) Heterocyclic modulators of lipid synthesis
ES2603570T3 (es) Preparación de colonoscopia
AR088189A1 (es) Metodo para producir acido libre de glufosinato p
JP2014507477A5 (es)
EA201500320A1 (ru) Композиция (варианты) и раствор для очищения толстой кишки, лекарственное средство, набор и способ очищения толстой кишки (варианты)
EA201391371A1 (ru) Фармацевтическая композиция ситаглиптина

Legal Events

Date Code Title Description
FG Grant, registration